Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIC+TAE with Tislelizumab and Surufatinib in Intrahepatic Cholangiocarcinoma
NCT06239532Phase 2Active, not recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Sep 2022
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in intrahepatic cholangiocarcinoma (ICC), sponsored by Qilu Hospital of Shandong University. Primary endpoint: Objective Response Rate at 24 months. Started Sep 2022; status: active, not recruiting.
02
Drugs
tislelizumab
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT06239532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06239532.